$PLRX
PLIANT THERAPEUTICS, INC.

2023 Q4 Form 10-Q Financial Statement

#000174647323000074 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $13.85M $15.35M
YoY Change -2.79% 73.98%
% of Gross Profit
Research & Development $33.18M $32.34M
YoY Change 32.13% 31.43%
% of Gross Profit
Depreciation & Amortization $464.0K $500.0K
YoY Change 1.98% 0.0%
% of Gross Profit
Operating Expenses $47.04M $47.69M
YoY Change 19.49% 42.65%
Operating Profit -$47.69M
YoY Change 49.26%
Interest Expense $5.928M $317.0K
YoY Change 153.33% -76.2%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$41.11M -$41.49M
YoY Change 17.25% 35.52%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$41.11M -$41.49M
YoY Change 17.25% 35.51%
Net Earnings / Revenue
Basic Earnings Per Share -$0.70
Diluted Earnings Per Share -$0.69 -$0.70
COMMON SHARES
Basic Shares Outstanding 59.90M shares 59.83M shares
Diluted Shares Outstanding 59.69M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $494.2M $523.6M
YoY Change 49.23% 45.35%
Cash & Equivalents $63.23M $57.68M
Short-Term Investments $431.0M $465.9M
Other Short-Term Assets $8.260M $8.600M
YoY Change 17.03% 106.78%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00
Other Receivables $2.997M $2.100M
Total Short-Term Assets $505.5M $534.3M
YoY Change 48.54% 46.01%
LONG-TERM ASSETS
Property, Plant & Equipment $3.567M $3.969M
YoY Change -20.49% -17.3%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $392.0K $392.0K
YoY Change -0.51% -1.26%
Total Long-Term Assets $6.652M $6.129M
YoY Change -35.43% -45.35%
TOTAL ASSETS
Total Short-Term Assets $505.5M $534.3M
Total Long-Term Assets $6.652M $6.129M
Total Assets $512.2M $540.5M
YoY Change 46.07% 43.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.531M $3.360M
YoY Change 186.77% 4.8%
Accrued Expenses $10.22M $8.310M
YoY Change -54.24% -59.08%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $28.52M $27.40M
YoY Change 19.28% 4.72%
LONG-TERM LIABILITIES
Long-Term Debt $10.05M $10.00M
YoY Change 1.26% -28.7%
Other Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $10.05M $10.00M
YoY Change -24.73% -28.7%
TOTAL LIABILITIES
Total Short-Term Liabilities $28.52M $27.40M
Total Long-Term Liabilities $10.05M $10.00M
Total Liabilities $38.58M $37.42M
YoY Change 3.51% -6.9%
SHAREHOLDERS EQUITY
Retained Earnings -$499.7M -$458.6M
YoY Change 47.67% 51.19%
Common Stock $973.0M $963.6M
YoY Change 48.84% 49.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $473.6M $503.0M
YoY Change
Total Liabilities & Shareholders Equity $512.2M $540.5M
YoY Change 46.07% 43.29%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$41.11M -$41.49M
YoY Change 17.25% 35.51%
Depreciation, Depletion And Amortization $464.0K $500.0K
YoY Change 1.98% 0.0%
Cash From Operating Activities -$25.10M -$36.22M
YoY Change -19.65% 95.8%
INVESTING ACTIVITIES
Capital Expenditures $61.00K $90.00K
YoY Change -63.25% -112.93%
Acquisitions
YoY Change
Other Investing Activities $31.98M $38.35M
YoY Change 58.42% -121.6%
Cash From Investing Activities $31.92M $38.26M
YoY Change 59.43% -121.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 219.0K 700.0K
YoY Change -22.89% -99.68%
NET CHANGE
Cash From Operating Activities -25.10M -36.22M
Cash From Investing Activities 31.92M 38.26M
Cash From Financing Activities 219.0K 700.0K
Net Change In Cash 7.038M 2.740M
YoY Change -164.37% -85.98%
FREE CASH FLOW
Cash From Operating Activities -$25.10M -$36.22M
Capital Expenditures $61.00K $90.00K
Free Cash Flow -$25.16M -$36.31M
YoY Change -19.88% 103.97%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1983000 usd
CY2023Q3 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
83000 usd
CY2022Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
83000 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10640000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7058000 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
534335000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
340311000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3969000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4486000 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1768000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5422000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-458639000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-338412000 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1907000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1958000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
503048000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
313342000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
540464000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
350613000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1482000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1580000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7720000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32339000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24606000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
94614000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
71822000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15346000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8823000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
44074000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25698000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
47685000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
33429000 usd
us-gaap Operating Expenses
OperatingExpenses
97520000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-47685000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-31947000 usd
plrx Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
17827000 usd
plrx Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
2013000 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
317000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
301000 usd
us-gaap Interest Expense
InterestExpense
946000 usd
us-gaap Interest Expense
InterestExpense
474000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-41487000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-30615000 usd
us-gaap Net Income Loss
NetIncomeLoss
-120227000 usd
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.70
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.70
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59688451 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59688451 shares
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
269915000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11923000 usd
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
627000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-37548000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
561920000 usd
CY2023Q2 plrx Adjustments To Additional Paid In Capital Public Offering Expenses
AdjustmentsToAdditionalPaidInCapitalPublicOfferingExpenses
133000 usd
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-910000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-41192000 usd
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
392000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
394000 usd
CY2023Q3 us-gaap Assets
Assets
540464000 usd
CY2022Q4 us-gaap Assets
Assets
350613000 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3360000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1580000 usd
CY2023Q3 plrx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
13664000 usd
CY2022Q4 plrx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
11218000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8310000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8658000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2061000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2457000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
27395000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23913000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3429000 usd
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
10021000 usd
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
9929000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
37416000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
37271000 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59890980 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59890980 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48941254 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48941254 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
6000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
5000 usd
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
963588000 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
653707000 usd
us-gaap Operating Expenses
OperatingExpenses
138688000 usd
us-gaap Net Income Loss
NetIncomeLoss
-88261000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-41487000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-41487000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-30615000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30615000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-120227000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-120227000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-88261000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-88261000 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.22
CY2023Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
3661000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13046000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
774000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10362000 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
334000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-41487000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
503048000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
199059000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
51000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3531000 usd
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-749000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-28100000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
173793000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
446000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3403000 usd
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-309000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-29546000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
147788000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
808000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4808000 usd
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1195000 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
215400000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
336994000 usd
us-gaap Net Income Loss
NetIncomeLoss
-120227000 usd
us-gaap Net Income Loss
NetIncomeLoss
-88261000 usd
us-gaap Depreciation
Depreciation
1377000 usd
us-gaap Depreciation
Depreciation
1368000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
35331000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
11743000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1833000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1260000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
10215000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
264000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1983000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-516000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3583000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2605000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-367000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-441000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1797000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
254000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2082000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
8315000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2004000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1369000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-91259000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-63392000 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
525572000 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
289402000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
367499000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
120770000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
860000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1594000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-158933000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-170226000 usd
plrx Proceeds From Issuances Of Common Stock Under Benefit Plans
ProceedsFromIssuancesOfCommonStockUnderBenefitPlans
4769000 usd
plrx Proceeds From Issuances Of Common Stock Under Benefit Plans
ProceedsFromIssuancesOfCommonStockUnderBenefitPlans
1305000 usd
plrx Payments Of Deferred Offering Costs
PaymentsOfDeferredOfferingCosts
834000 usd
plrx Payments Of Deferred Offering Costs
PaymentsOfDeferredOfferingCosts
786000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
150000 usd
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0 usd
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
10000000 usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
270251000 usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
216201000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
274186000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
226570000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
23994000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7048000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57679000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
44617000 usd
us-gaap Interest Paid Net
InterestPaidNet
864000 usd
us-gaap Interest Paid Net
InterestPaidNet
332000 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
51000 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
2253000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
33000 usd
plrx Deferred Offering Costs In Accounts Payable And Accrued Liabilities
DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities
0 usd
plrx Deferred Offering Costs In Accounts Payable And Accrued Liabilities
DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities
14000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
950000 usd
plrx Decrease In Right Of Use Assets And Liabilities From Lease Modifications
DecreaseInRightOfUseAssetsAndLiabilitiesFromLeaseModifications
1821000 usd
plrx Decrease In Right Of Use Assets And Liabilities From Lease Modifications
DecreaseInRightOfUseAssetsAndLiabilitiesFromLeaseModifications
0 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses as well as the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, stock-based compensation expense and accruals and prepayments for research and development costs. The Company assesses estimates on an ongoing basis, however, actual results could materially differ from those estimates.</span></div>
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
520086000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1907000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
518179000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
327771000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
45000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2003000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
325813000 usd
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12187000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11327000 usd
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8218000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6841000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3969000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4486000 usd
CY2022Q3 us-gaap Depreciation
Depreciation
500000 usd
CY2023Q3 us-gaap Depreciation
Depreciation
500000 usd
us-gaap Depreciation
Depreciation
1400000 usd
us-gaap Depreciation
Depreciation
1400000 usd
CY2023Q3 plrx Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
6700000 usd
CY2022Q4 plrx Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
3421000 usd
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
95000 usd
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1427000 usd
CY2023Q3 plrx Prepaid Licenses Current
PrepaidLicensesCurrent
1138000 usd
CY2022Q4 plrx Prepaid Licenses Current
PrepaidLicensesCurrent
959000 usd
CY2023Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
2039000 usd
CY2022Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
1078000 usd
CY2023Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
668000 usd
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
173000 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10640000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7058000 usd
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6680000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7200000 usd
CY2023Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1630000 usd
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1458000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8310000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8658000 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
5455000 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
4545000 usd
CY2023Q3 plrx Long Term Debt Maturity After Year Four
LongTermDebtMaturityAfterYearFour
0 usd
CY2023Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10000000 usd
CY2023Q3 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
113000 usd
CY2023Q3 plrx Long Term Debt Accretion Of Final Payment
LongTermDebtAccretionOfFinalPayment
134000 usd
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
10021000 usd
CY2023Q3 plrx Number Of Classes Of Stock Authorized
NumberOfClassesOfStockAuthorized
2 class
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Common Stock Voting Rights
CommonStockVotingRights
The holders of shares of common stock are entitled to one vote for each share of common stock held at any meeting of stockholders.
us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
12575004 shares
CY2023Q3 plrx Valuation Allowance As Percentage On Deferred Tax Assets
ValuationAllowanceAsPercentageOnDeferredTaxAssets
1
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10363000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
plrx Contractual Arrangements Cancellation Period
ContractualArrangementsCancellationPeriod
P30D
CY2023Q3 plrx Decrease In Right Of Use Assets And Liabilities From Lease Modifications
DecreaseInRightOfUseAssetsAndLiabilitiesFromLeaseModifications
1800000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
569000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1624000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2193000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
132000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2061000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9M9D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.133
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
698000 usd
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
655000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
2142000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
1783000 usd
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
130000 usd
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
131000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
620000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
407000 usd
CY2023Q3 us-gaap Lease Cost
LeaseCost
828000 usd
CY2022Q3 us-gaap Lease Cost
LeaseCost
786000 usd
us-gaap Lease Cost
LeaseCost
2762000 usd
us-gaap Lease Cost
LeaseCost
2190000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
2600000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1900000 usd
CY2023Q3 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
200000 usd
CY2022Q3 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000 usd
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
800000 usd
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
600000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7769360 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5997821 shares
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-41487000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-30615000 usd
us-gaap Net Income Loss
NetIncomeLoss
-120227000 usd
us-gaap Net Income Loss
NetIncomeLoss
-88261000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-41487000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-41487000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-30615000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30615000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-120227000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-120227000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-120227000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-120227000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-88261000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-88261000 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59688451 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59688451 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46799058 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46799058 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58319608 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58319608 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39735342 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39735342 shares
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.70
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.70
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.65
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.65
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.22

Files In Submission

Name View Source Status
plrx-20230930_pre.xml Edgar Link unprocessable
0001746473-23-000074-index-headers.html Edgar Link pending
0001746473-23-000074-index.html Edgar Link pending
0001746473-23-000074.txt Edgar Link pending
0001746473-23-000074-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
plrx-20230930.htm Edgar Link pending
plrx-20230930.xsd Edgar Link pending
plrx-20230930xex311.htm Edgar Link pending
plrx-20230930xex312.htm Edgar Link pending
plrx-20230930xex321.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
plrx-20230930_cal.xml Edgar Link unprocessable
plrx-20230930_def.xml Edgar Link unprocessable
plrx-20230930_lab.xml Edgar Link unprocessable
plrx-20230930_htm.xml Edgar Link completed
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending